PHARMACISTS in Australia have this week for the first time the opportunity to exercise the option of substituting an 'a' flagged biosimilar in consultation with the patient but without necessarily referencing the prescriber.
MSD has confirmed the availability of biosimilar Brenzys (etanercept), the originator brand being Enbrel from Pfizer, on the Pharmaceutical Benefits Scheme (PBS) from 01 Apr (PD yesterday).
Dr Mona Marabani, rheumatologist and chair of the biosimilars working group of the Australian Rheumatology Association said it was important that the healthcare community worked together to build understanding of the new products.
"Information and education will become increasingly important as more biosimilars become available alongside the originator biologics and careful long term monitoring will be vital," she explained.
MSD said it expected to launch an ongoing range of biosimilars in the coming years, focusing on oncology and immunology items where the value of originator products was estimated at over $850m annually.
Coffs Harbour clinical pharmacist David Metcalf emphasised the need for education for pharmacists, prescribers and patients, the need to track changes in medication, especially via e-health records and the importance of consulting with prescribers on biosimilar switching.
Being 'a' flagged means pharmacists can substitute the items at the point of dispensing, subject to choice by the patient and the prescriber.
Significant savings for the health system are expected as funded biosimilars are also likely to drive down the prices of originator brands, Metcalf said.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Apr 17
